Form 4: ClearPoint Neuro Director Acquires Stock Units

ClearPoint Neuro, Inc. Director B. Kristine Johnson acquired 12,820 restricted stock units on May 21, 2026.

Summary

• B. Kristine Johnson, a Director at ClearPoint Neuro, Inc., acquired 12,820 restricted stock units (RSUs) on May 21, 2026.
• These RSUs represent a contingent right to receive one share of CLPT common stock per unit.
• The RSUs are set to vest on the earlier of the first anniversary of the grant date or the day before the Company's 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard equity award to a director rather than a discretionary purchase or sale of stock.

Positives

• Director acquisition of stock units can signal confidence in the company's future prospects.
• The acquisition of 12,820 RSUs indicates a significant grant to a key insider.

Future Outlook

The vesting schedule for the restricted stock units is tied to the first anniversary of the grant date or the day before the Company's 2027 annual meeting of stockholders, indicating a medium-term outlook for the realization of these equity awards.

Industry Context

StockSavvy.ai notes that insider stock unit acquisitions are common in the biotechnology and medical device sectors, reflecting long-term incentive structures for key personnel.

Stakeholder Impact

• Shareholders: The acquisition of RSUs by a director is a standard compensation practice and does not immediately impact share price, but it aligns director interests with long-term company performance.

Next Steps

• Vesting of the 12,820 restricted stock units on or before the day preceding the 2027 annual meeting of stockholders.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Form 4, Insider Transaction, Restricted Stock Units, Director, Equity Award